A global pharmaceutical company was exploring a potential partnership with one of several companies developing a new anti-CGRP to treat and prevent migraines

Cystic Fibrosis (CF) is a rare, life-shortening, genetic disorder which affects multiple organs, predominantly the lungs and pancreas. CF is caused by a defective cystic fibrosis transmembrane conductance regulator (CFTR) gene, and both copies of the faulty CFTR gene must be inherited to develop CF. This defective CFTR gene causes the abnormal production of sweat and mucus.

Through sweating, CF patients lose excessive amounts of salt, causing abnormal heart rhythms, risk of shock, stroke, and decreased blood pressure. Mucus accumulating in the intestines and lungs results in malnutrition, poor growth, respiratory infections, breathing difficulties, and eventually permanent lung damage. Subsequently, lung disease is the most common cause of death in most CF patients.

Product X is seeking approval in locally advanced or metastatic urothelial carcinoma (i.e. bladder cancer) as a monotherapy and as a 2nd Line (2L) option

Product X is expected to gain accelerated approval based on an open label, single-arm Phase II study

Objective: Develop a clear understanding of US payer perceptions of key value drivers and potential price ranges, and to form the basis for preliminary payer value story and proposition

We are delighted to announce the promotion of Zameer Merchant to Principal at Windrose Consulting Group.

Historically, Spain has had one of the longest and most complicated reimbursement processes in Europe. This was seen to be due to its lengthy process in developing Therapeutic Positioning Reports (IPTs) and a lack of transparency in evaluation criteria. To counteract these claims, Spain is planning to reform its IPT process in 2021.

What Drove Spain to Change their IPT process?

IPTs, introduced in 2013, were initially expected to take 3 months for the Spanish Agency of Medicines & Health Products (AEMPS) research and analysis. However, in recent years AEMPS analysis has been taking over 9 months, plus additional time for evaluation by the autonomous communities (CCAAs) (1).

A global pharmaceutical company was developing a new product for the treatment of Parkinson’s disease; the product had a novel mechanism of action and was in early phase of clinical development

Windrose Consulting Group are pleased to announce the October promotions within our team.

Windrose Consulting Group acquires Parioforma as part of its global growth strategy to further enhance its capabilities in non-traditional markets.

A global pharmaceutical company’s R&D portfolio included several combination products across multiple different disease states.

A biopharmaceutical company was developing the first gene therapy for a rare disease. It was expected to be a one-time therapy that would replace the current chronic standard of care.

A global pharmaceutical company was planning to launch a next generation vaccine into a competitive market with the aim of replacing the current standard of care, which was a vaccine that they also owned.

A global pharmaceutical company was exploring a potential partnership with one of several companies developing a new anti-CGRP to treat and prevent migraines.

In recent years, there has been a growing interest between pharmaceutical companies and payers to implement Value Based Agreements (VBAs) based on clinical outcomes. VBAs are typically applied when access is not attained through “standard” value communication and negotiation, driven by uncertainties around the clinical evidence and / or financial impact of the drug in question. As more and more curative and transformative therapies such as gene therapies enter the market, payers are looking for innovative ways to pay for these next-generation medicines, which are often accompanied with an astronomical price tag.

Windrose Consulting Group collaborate with Cambridge University on a Executive education course on commercialization strategy

Ken Wilson announced as a Managing Partner.

Windrose Consulting Group is pleased to announce the addition of Matt Storer to the leadership team.  Matt joins as a Partner based in the London office, and will be leading the European Consulting Operations.